FABP1 and necrotizing enterocolitis: Nevertheless, the sample size in some studies was deemed insufficient to strengthen the reported findings, as was the case in studies on the potential of L-FABP as a biomarker for NEC [5], hepatocyte injury in patients after liver resection [29,30], and liver injury in patients with CHC [32].